CLIA Kit for Fibroblast Growth Factor 13 (FGF13)

6.17-500pg/mL

The minimum detectable dose of this kit is typically less than 2.42pg/mL

2h

This assay has high sensitivity and excellent specificity for detection of Fibroblast Growth Factor 13 (FGF13).
No significant cross-reactivity or interference between Fibroblast Growth Factor 13 (FGF13) and analogues was observed.

The stability of kit is determined by the loss rate of activity. The loss rate of this kit is less than 5% within the expiration date under appropriate storage condition.
To minimize extra influence on the performance, operation procedures and lab conditions, especially room temperature, air humidity, incubator temperature should be strictly controlled. It is also strongly suggested that the whole assay is performed by the same operator from the beginning to the end.

The microplate provided in this kit has been pre-coated with a monoclonal antibody specific to Fibroblast Growth Factor 13 (FGF13). A competitive inhibition reaction is launched between biotin labeled Fibroblast Growth Factor 13 (FGF13) and unlabeled Fibroblast Growth Factor 13 (FGF13) (Standards or samples) with the pre-coated antibody specific to Fibroblast Growth Factor 13 (FGF13). After incubation the unbound conjugate is washed off. Next, avidin conjugated to Horseradish Peroxidase (HRP) is added to each microplate well and incubated. The amount of bound HRP conjugate is reverse proportional to the concentration of Fibroblast Growth Factor 13 (FGF13) in the sample. Then the mixture of substrate A and B is added to generate glow light emission kinetics. Upon plate development, the intensity of the emitted light is reverse proportional to the Fibroblast Growth Factor 13 (FGF13) level in the sample or standard.